{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061548","form_type":"8-K","ticker":"VERA","cik":"0001831828","company_name":"Vera Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.847606+00:00","generated_at":"2026-06-08T07:32:48.919579+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vera Therapeutics Q3 net loss $20.1M ($0.45/diluted); cash $159.9M; hematuria resolution data at ASN","bullets":["Net loss of $20.1M ($0.45 per diluted share) vs $24.7M ($0.91) in Q3 2022.","Cash, cash equivalents and securities $159.9M; cash burn $67.0M in nine months.","Phase 2b OLE eGFR and proteinuria data expected Q1 2024; pivotal Phase 3 ORIGIN 3 enrolling.","At ASN Kidney Week: 80% of atacicept patients achieved hematuria resolution vs 5% placebo.","Enrollment of Phase 3 ORIGIN 3 estimated to complete H2 2024; topline data H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061548","json":"https://secwatch.observer/filing/0000950170-23-061548.json","markdown":"https://secwatch.observer/filing/0000950170-23-061548.md","text":"https://secwatch.observer/filing/0000950170-23-061548.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831828/000095017023061548/0000950170-23-061548-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831828/000095017023061548/vera-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:32:48.919579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"58a492e45e0508aa628da7210d214356dbf8ae07","claim":"Vera Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $20.1 million, EPS $0.45.","evidence_excerpt":"For the quarter ended September 30, 2023, the company reported a net loss of $20.1 million, or a net loss per diluted share of $0.45","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831828/000095017023061548/0000950170-23-061548-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"$20.1 million"},{"label":"EPS","value":"$0.45"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}